Kevin Bitterman Sells 62,693 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Kevin Bitterman sold 62,693 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $91.28, for a total transaction of $5,722,617.04. Following the sale, the director owned 28,520 shares of the company’s stock, valued at $2,603,305.60. The trade was a 68.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Kevin Bitterman also recently made the following trade(s):

• On Friday, December 12th, Kevin Bitterman sold 45,507 shares of Disc Medicine stock. The shares were sold at an average price of $92.39, for a total value of $4,204,391.73.
• On Tuesday, December 16th, Kevin Bitterman sold 68,923 shares of Disc Medicine stock. The shares were sold at an average price of $91.24, for a total value of $6,288,534.52.
• On Monday, December 15th, Kevin Bitterman sold 7,000 shares of Disc Medicine stock. The stock was sold at an average price of $91.87, for a total value of $643,090.00.
• On Friday, October 17th, Kevin Bitterman sold 70,000 shares of Disc Medicine stock. The stock was sold at an average price of $88.91, for a total value of $6,223,700.00.
• On Thursday, October 16th, Kevin Bitterman sold 1,425 shares of Disc Medicine stock. The shares were sold at an average price of $77.11, for a total value of $109,881.75.
• On Wednesday, October 15th, Kevin Bitterman sold 22,160 shares of Disc Medicine stock. The stock was sold at an average price of $77.23, for a total value of $1,711,416.80.
• On Wednesday, October 8th, Kevin Bitterman sold 71,961 shares of Disc Medicine stock. The stock was sold at an average price of $70.58, for a total value of $5,079,007.38.
• On Tuesday, October 7th, Kevin Bitterman sold 18,039 shares of Disc Medicine stock. The shares were sold at an average price of $68.38, for a total transaction of $1,233,506.82.

Disc Medicine Trading Down 0.6%

Shares of Disc Medicine stock traded down $0.53 during trading on Tuesday, hitting $91.47. The stock had a trading volume of 639,414 shares, compared to its average volume of 536,679. Disc Medicine, Inc. has a 1 year low of $30.82 and a 1 year high of $99.50. The stock has a 50 day simple moving average of $86.99 and a 200 day simple moving average of $68.22. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $3.45 billion, a PE ratio of -17.10 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29). On average, research analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on IRON. National Bankshares set a $153.00 price target on Disc Medicine in a report on Friday, October 17th. Truist Financial lifted their target price on Disc Medicine from $86.00 to $114.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Wells Fargo & Company increased their price target on shares of Disc Medicine from $91.00 to $109.00 and gave the stock an “overweight” rating in a research report on Tuesday. Stifel Nicolaus assumed coverage on shares of Disc Medicine in a report on Monday, November 3rd. They set a “buy” rating and a $125.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.00.

Institutional Investors Weigh In On Disc Medicine

Several institutional investors have recently made changes to their positions in IRON. Aster Capital Management DIFC Ltd acquired a new stake in shares of Disc Medicine in the third quarter worth $38,000. CWM LLC raised its holdings in Disc Medicine by 213.5% in the 2nd quarter. CWM LLC now owns 1,044 shares of the company’s stock worth $55,000 after acquiring an additional 711 shares during the period. Avanza Fonder AB acquired a new position in Disc Medicine during the 2nd quarter worth $57,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Disc Medicine by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock worth $71,000 after acquiring an additional 181 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in Disc Medicine by 8.9% during the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock valued at $133,000 after acquiring an additional 206 shares during the period. 83.70% of the stock is currently owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.